Bavarian Nordic has secured a four-year contract from the UK Government to supply its MVA-BN vaccine, which is used for the prevention of mpox and smallpox. This agreement may enhance the company’s position in the vaccine market and ensure a steady revenue stream over the contract period. Manufacturers and suppliers in the vaccine sector could see increased competition as Bavarian Nordic strengthens its portfolio and capabilities in public health initiatives.
Source: pharmaceutical-technology.com · Image: COVIran Barekat vaccine production 10 by Sadegh Nikgostar, CC BY 4.0, via Wikimedia Commons
For investors and analysts:
See in seconds what each company actually manufactures, together with its certificates and compliance status.
This isn’t marketing language — it’s factual data on APIs, FDFs, dossiers, and direct producer contacts.
Open the full market picture for your next decision →
Open the full market picture for your next decision →
